Certara (CERT) – Accelerating Medicines with Biosimulation
As seen on CNBC** Certara is the global leader in biosimulation, a powerful and proven…
Certara2021年4月27日
Part 3: Oligonucleotide therapeutic development: Clinical pharmacology considerations
In the last few years, the pharmaceutical industry has invested in developing Complex Biologics including…
Jim Gallagher2021年4月21日
Part 2: Oligonucleotide therapeutic development: Pre-clinical and translational considerations
In the last few years, the pharmaceutical industry has invested in developing Complex Biologics including…
Jim Gallagher2021年4月21日
Part 1: What are oligonucleotide therapeutics, and how do they work?
In the last few years, the pharmaceutical industry has invested in developing Complex Biologics including…
Jim Gallagher2021年4月21日
Predicting the Effect of the Dulaglutide-Mediated Gastric Emptying Delay on Drug Exposure
The European Medicines Agency (EMA) recently approved dulaglutide (Trulicity®) at higher doses (3 mg and…
Jim Gallagher2021年4月1日
Systematic literature review of cross-protective effect of HPV vaccines based on data from randomized clinical trials and real-world evidence
The extent of cross-protection provided by currently licensed bivalent and quadrivalent HPV vaccines versus direct…
Jim Gallagher2021年3月18日
Sealing Pharma Commercialization Deals: Creating Optimal Value for Investors
It is crucial for biotech developers to engage in early commercial market assessment to generate…
Jim Gallagher2021年3月5日
BPS Article: Model‐Informed Drug Repurposing: a Pharmacometric Approach to Novel Pathogen Preparedness, Response and Retrospection
Abstract During a pandemic caused by a novel pathogen (NP), drug repurposing offers the potential…
Certara2021年2月9日
How drug developers can avoid these common mistakes to secure a deal
Emerging biotech companies sometimes lack all of the experience, expertise, or financial capital to successfully…
Jim Gallagher2021年1月21日
